TrialID,sponsor_type,manual,Primary_sponsor,study_arm,url,Scientific_title,Conditions,Date_enrollment_format,control_arm,randomisation,blinding,subject_blind,caregiver_blind,investigator_blind,outcome_blind,analyst_blind,prospective,Source_registry,phase_clean,region_Africa,region_N_America,region_L_America,region_Asia,region_Europe,region_Oceania,multicentre,primary_purpose,sample_size,vaccine,conventional,traditional,Bridging_flag,Study_design,Day_inferred,Date_registration_format,Phase,Public_title,Countries,Interventions
EUCTR2018-003117-18-ES,non_industry,investigator,Dr. Jordi Carratalà Fernández (Servicio de Enfermedades Infecciosas) del Hospital Universitario de Bellvitge,im,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-003117-18,"A phase III randomized, controlled, open label multicenter clinical trial, with two parallel groups, to evaluate the efficacy of albumin administration in patients hospitalized with community-acquired pneumonia (ALBUCAP)",Community-acquired pneumonia (CAP) <br>MedDRA version: 20.0Level: PTClassification code 10035664Term: PneumoniaSystem Organ Class: 10021881 - Infections and infestations;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08],2019-07-10,Yes,Yes,No,No,No,No,No,No,Yes,EUCTR,Phase 3,No,No,No,No,Yes,No,Yes,NA,360,NA,NA,NA,NCT04071041,"Controlled: yes<br>Randomised: yes<br>Open: yes<br>Single blind: no<br>Double blind: no<br>Parallel group: yes<br>Cross over: no<br>Other: no<br>If controlled, specify comparator, Other Medicinial Product: no<br>Placebo: no<br>Other: yes<br>Other specify the comparator: STANDARD OF CARE<br>Number of treatment arms in the trial: 2<br>",FALSE,2019-04-12,Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): noTherapeutic confirmatory - (Phase III): yesTherapeutic use (Phase IV): no,To evaluate the efficacy of albumin administration in patients hospitalized with community-acquired pneumonia (ALBUCAP),Spain,<br>Trade Name: Albutein 20% solución para perfusión<br>Product Name: Albúmina<br>Pharmaceutical Form: Solution for infusion<br>INN or Proposed INN: ALBUMINA<br>CAS Number: 9006-53-5<br>Current Sponsor code: ALBUMINA<br>Other descriptive name: HUMAN SERUM ALBUMIN<br>Concentration unit: g gram(s)<br>Concentration type: equal<br>Concentration number: 20-<br><br>
NCT03380507,industry,non_industry,Hamad Medical Corporation,im,https://clinicaltrials.gov/show/NCT03380507,"Evaluation of Hydrocortisone, Vitamin C and Thiamine for the Treatment of Septic Shock",Septic Shock;Critical Illness,2018-03-17,Yes,Yes,No,No,No,No,No,No,Yes,CT.gov,Phase 3,No,No,No,Yes,No,No,NA,Treatment,212,NA,NA,NA,FALSE,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,FALSE,2017-12-07,Phase 2/Phase 3,"Evaluation of Hydrocortisone, Vitamin C and Thiamine for the Treatment of Septic Shock",Qatar,Drug: Triple therapy group
